Karim A Meijer1, Vinod Dasa2. 1. LSU Department of Orthopaedics, 1542 Tulane Ave., Box T6-7, New Orleans, LA 70112, United States. Electronic address: Karim.Meijer@gmail.com. 2. LSU Department of Orthopaedics, 1542 Tulane Ave., Box T6-7, New Orleans, LA 70112, United States.
Abstract
BACKGROUND: Primary total knee arthroplasty is a high volume procedure which is expected to grow dramatically in the near future. The decision to resurface the patella has been discussed extensively in the literature yet the financial implications of resurfacing versus not resurfacing have not been demonstrated. METHODS: We identified all randomized controlled trials comparing patellar resurfacing to nonresurfacing in the past ten years and identified the total number of patellofemoral revision surgeries for both resurfaced and nonresurfaced patellas in each study. An expected-value decision tree analysis was created using only data from the randomized controlled trials. Actual costs collected from Medicare reimbursement rates were then applied to the model and a sensitivity analysis was performed. RESULTS: The expected value of primary total knee arthroplasty with patellar resurfacing was $13,788.48 while a primary total knee arthroplasty without patellar resurfacing was $14,016.41 after five years. The difference represents an additional $227.92 of Medicare dollars for every primary total knee arthroplasty performed without patellar resurfacing at five years. The model remains valid as long as patellofemoral revision rates after patellar resurfacing remain below 3.54% and patellofemoral revision rates after nonresurfaced patellas remain above 0.77%. CONCLUSIONS: While initially counterintuitive, resurfacing the patella during a primary total knee arthroplasty is the optimal financial strategy from a Medicare perspective over a mid term period.
BACKGROUND: Primary total knee arthroplasty is a high volume procedure which is expected to grow dramatically in the near future. The decision to resurface the patella has been discussed extensively in the literature yet the financial implications of resurfacing versus not resurfacing have not been demonstrated. METHODS: We identified all randomized controlled trials comparing patellar resurfacing to nonresurfacing in the past ten years and identified the total number of patellofemoral revision surgeries for both resurfaced and nonresurfaced patellas in each study. An expected-value decision tree analysis was created using only data from the randomized controlled trials. Actual costs collected from Medicare reimbursement rates were then applied to the model and a sensitivity analysis was performed. RESULTS: The expected value of primary total knee arthroplasty with patellar resurfacing was $13,788.48 while a primary total knee arthroplasty without patellar resurfacing was $14,016.41 after five years. The difference represents an additional $227.92 of Medicare dollars for every primary total knee arthroplasty performed without patellar resurfacing at five years. The model remains valid as long as patellofemoral revision rates after patellar resurfacing remain below 3.54% and patellofemoral revision rates after nonresurfaced patellas remain above 0.77%. CONCLUSIONS: While initially counterintuitive, resurfacing the patella during a primary total knee arthroplasty is the optimal financial strategy from a Medicare perspective over a mid term period.
Authors: Sorin Radu Fleaca; Cosmin Ioan Mohor; Horatiu Dura; Radu Chicea; Calin Mohor; Adrian Boicean; Mihai Dan Roman Journal: Exp Ther Med Date: 2021-12-01 Impact factor: 2.447
Authors: Elsa M R Marques; Jane Dennis; Andrew D Beswick; Julian Higgins; Howard Thom; Nicky Welton; Amanda Burston; Linda Hunt; Michael R Whitehouse; Ashley W Blom Journal: BMJ Open Date: 2021-01-06 Impact factor: 2.692